D Perrotti

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. pmc Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
    Danilo Perrotti
    Comprehensive Cancer Center The Ohio State University Columbus, OH USA
    Cell Cycle 11:4300. 2012
  2. pmc Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
    Houda Alachkar
    Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    J Hematol Oncol 6:21. 2013
  3. pmc Protein phosphatase 2A: a target for anticancer therapy
    Danilo Perrotti
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210 2207, USA
    Lancet Oncol 14:e229-38. 2013
  4. ncbi request reprint Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias
    Danilo Perrotti
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Cancer Metastasis Rev 27:159-68. 2008
  5. pmc Chronic myeloid leukemia: mechanisms of blastic transformation
    Danilo Perrotti
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 41230, USA
    J Clin Invest 120:2254-64. 2010
  6. pmc ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia
    D Perrotti
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Br J Cancer 95:775-81. 2006
  7. ncbi request reprint BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention
    Danilo Perrotti
    Human Cancer Genetics Program, Depatment of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center and Center for RNA Biology, The Ohio State University, Columbus, OH 43210 2207, USA
    Leuk Lymphoma 52:30-44. 2011
  8. ncbi request reprint From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way
    Danilo Perrotti
    The Molecular Biology and Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43240, USA
    Clin Cancer Res 13:1638-42. 2007
  9. ncbi request reprint Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia
    Shujun Liu
    Divisions of Hematology Oncology, Department of Internal Medicine and the Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA
    Cancer Res 65:1277-84. 2005
  10. ncbi request reprint The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein
    Paolo Neviani
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer Cell 8:355-68. 2005

Research Grants

Collaborators

Detail Information

Publications49

  1. pmc Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
    Danilo Perrotti
    Comprehensive Cancer Center The Ohio State University Columbus, OH USA
    Cell Cycle 11:4300. 2012
    ..Comment on: Kusio-Kobialka M, et al. Cell Cycle 2012; 11:4069-78...
  2. pmc Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
    Houda Alachkar
    Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    J Hematol Oncol 6:21. 2013
    ..We examined here the preclinical activity of silvestrol in FLT3-ITD and FLT3 wild-type (wt) AML...
  3. pmc Protein phosphatase 2A: a target for anticancer therapy
    Danilo Perrotti
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210 2207, USA
    Lancet Oncol 14:e229-38. 2013
    ..Here, we discuss PP2A as a druggable tumour suppressor in view of the possible introduction of PP2A-activating drugs into anticancer therapeutic protocols...
  4. ncbi request reprint Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias
    Danilo Perrotti
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Cancer Metastasis Rev 27:159-68. 2008
    ..Herein, we review current knowledge of PP2A biology and function with particular emphasis on its tumor suppressor activity and possible therapeutic implications in cancer...
  5. pmc Chronic myeloid leukemia: mechanisms of blastic transformation
    Danilo Perrotti
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 41230, USA
    J Clin Invest 120:2254-64. 2010
    ..The latter responds poorly to treatment and is usually fatal. Here, we discuss what is known about the molecular mechanisms leading to blastic transformation of CML and propose some novel therapeutic approaches...
  6. pmc ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia
    D Perrotti
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Br J Cancer 95:775-81. 2006
    ..Thus, the combination of PP2A phosphatase-activating and BCR/ABL kinase-inhibiting drugs may represent a powerful therapeutic strategy for blast crisis CML patients...
  7. ncbi request reprint BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention
    Danilo Perrotti
    Human Cancer Genetics Program, Depatment of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center and Center for RNA Biology, The Ohio State University, Columbus, OH 43210 2207, USA
    Leuk Lymphoma 52:30-44. 2011
    ....
  8. ncbi request reprint From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way
    Danilo Perrotti
    The Molecular Biology and Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43240, USA
    Clin Cancer Res 13:1638-42. 2007
    ....
  9. ncbi request reprint Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia
    Shujun Liu
    Divisions of Hematology Oncology, Department of Internal Medicine and the Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA
    Cancer Res 65:1277-84. 2005
    ..These results suggest a novel mechanism for gene silencing mediated by RUNX1/MTG8 and support the combination of HDAC and DNMT inhibitors as a novel therapeutic approach for t(8;21) AML...
  10. ncbi request reprint The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein
    Paolo Neviani
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer Cell 8:355-68. 2005
    ..Thus, functional inactivation of PP2A is essential for BCR/ABL leukemogenesis and, perhaps, required for blastic transformation...
  11. pmc Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells
    Brian Becknell
    Medical Scientist Program, Department of Internal Medicine, College of Medicine and Public Health, The Ohio State University, Columbus, OH 43210, USA
    Blood 109:2481-7. 2007
    ..Thus, Hlx expression in activated NK cells temporally controls and limits the monokine-induced production of IFN-gamma, in part through the targeted depletion of STAT4...
  12. pmc Modulation of DNA methylation by a sesquiterpene lactone parthenolide
    Zhongfa Liu
    Division of Pharmaceutics, Colleges of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    J Pharmacol Exp Ther 329:505-14. 2009
    ..Hence, our study established parthenolide as an effective DNA methylation inhibitor, representing a novel prototype for DNMT1 inhibitor discovery and development from natural structural-diversified sesquiterpene lactones...
  13. pmc MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
    Ramiro Garzon
    Department of Medicine, Ohio State University, Columbus, 43210, USA
    Blood 113:6411-8. 2009
    ....
  14. pmc The PP2A inhibitor SET regulates natural killer cell IFN-gamma production
    Rossana Trotta
    Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    J Exp Med 204:2397-405. 2007
    ..Thus, SET expression is essential for suppressing PP2A phosphatase activity that would otherwise limit NK cell antitumoral and/or antiinflammatory functions by impairing NK cell production of IFN-gamma...
  15. pmc Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia
    Shujun Liu
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:2364-73. 2008
    ..Our results unveil the Sp1/NF-kappaB pathway as a modulator of DNA methyltransferase activity in human cancer and identify bortezomib as a novel epigenetic-targeting drug...
  16. pmc Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
    Flavia Pichiorri
    Department of Molecular Virology, Comprehensive Cancer Center, Ohio State University, Columbus, 43210, USA
    Cancer Cell 18:367-81. 2010
    ..The results suggest that these miRNAs are positive regulators of p53 and that their downregulation plays a key role in MM development...
  17. pmc Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia
    Shujun Liu
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 17:333-47. 2010
    ....
  18. pmc The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells
    Rossana Trotta
    Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, 460 West 12th Ave, Columbus, OH 43210, USA
    Blood 117:2378-84. 2011
    ..These data provide evidence that granzyme B gene expression and therefore human NK-cell cytotoxicity can be regulated by the PP2A-SET interplay...
  19. pmc TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells
    Rossana Trotta
    Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, Columbus, OH 43210, USA
    J Immunol 181:3784-92. 2008
    ..This effect was accentuated in cells overexpressing SMAD3. Collectively, our results indicate that TGF-beta inhibits CD16-mediated human NK cell IFN-gamma production and ADCC, and these effects are mediated via SMAD3...
  20. pmc miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts
    Anna M Eiring
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    Cell 140:652-65. 2010
    ..Altogether, these data reveal the dual ability of a microRNA to control cell fate both through base pairing with mRNA targets and through a decoy activity that interferes with the function of regulatory proteins...
  21. pmc Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target
    J G Harb
    1 Human Cancer Genetics Program, Department Molecular Virology Immunology and Medical Genetics, Columbus, OH, USA 2 Blood Center of Wisconsin, Blood Research Institute, Milwaukee, WI, USA
    Leukemia 27:1996-2005. 2013
    ..Thus, suppression of the antiapoptotic potential of Bcl-xL together with BAD activation represents an effective pharmacological approach for patients undergoing blastic transformation. ..
  22. pmc Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells
    Don M Benson
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210 1240, USA
    Blood 113:2706-14. 2009
    ..The effect results at least in part via enhanced MAPK-mediated modulation of p27 and CDK4. Collectively the data reveal a novel mechanism by which SCF enhances cellular proliferation in combination with IL-2/15 in primary human NK cells...
  23. pmc Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method
    Zhongfa Liu
    College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Nucleic Acids Res 35:e31. 2007
    ..Our data support the use of our LC-MS/MS method for clinical pharmacodynamic determination of changes in GDM in vivo...
  24. pmc Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice
    Stefan Costinean
    Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 114:1374-82. 2009
    ..We hypothesize that miR-155, by down-modulating Ship and C/EBPbeta, initiates a chain of events that leads to the accumulation of large pre-B cells and acute lymphoblastic leukemia/high-grade lymphoma...
  25. pmc FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia
    Paolo Neviani
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, USA
    J Clin Invest 117:2408-21. 2007
    ..Altogether, these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients...
  26. pmc A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation
    Mario Notari
    Human Cancer Genetics Program, The Ohio State University Medical Center, Columbus, OH 43240, USA
    Blood 107:2507-16. 2006
    ..Thus, BCR/ABL-dependent enhancement of HNRPK translation-regulation is important for BCR/ABL leukemogenesis and, perhaps, it might contribute to blast crisis transformation...
  27. ncbi request reprint Translational regulation by the p210 BCR/ABL oncoprotein
    Danilo Perrotti
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics and the Comprehensive Cancer Center, The Ohio State University, Columbus OH 43210, USA
    Oncogene 23:3222-9. 2004
    ..The identification of mRNA targets translationally regulated by RNA binding proteins overexpressed in tumor cells may lead to the development of therapeutic strategies aimed at modulating the translation rate of specific mRNAs...
  28. ncbi request reprint Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study
    Peter Paschka
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 24:3904-11. 2006
    ..To analyze the prognostic impact of mutated KIT (mutKIT) in core-binding factor acute myeloid leukemia (AML) with inv(16)(p13q22) and t(8;21)(q22;q22)...
  29. ncbi request reprint Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells
    Shujun Liu
    Division of Hematology, The Ohio State University, 320 West 10th Avenue, Columbus, OH 43210, USA
    J Pharmacol Exp Ther 321:953-60. 2007
    ....
  30. pmc Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis
    Anna M Eiring
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, USA
    Blood 111:816-28. 2008
    ..Thus, the complexity of the mRNA/RBP network, together with the discovery of E2F3 as an hnRNP-A1-regulated factor, outlines the relevant role played by RBPs in posttranscriptional regulation of CML development and progression...
  31. pmc High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation
    Ji Suk Chang
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, OH 23240, USA
    Blood 110:994-1003. 2007
    ..Furthermore, these findings suggest the inclusion of clinically relevant MAPK inhibitors in the therapy of CML-BC...
  32. ncbi request reprint Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus OH 43210, USA
    J Clin Oncol 23:9234-42. 2005
    ..To test the prognostic significance of ETS-related gene (ERG) expression in cytogenetically normal primary acute myeloid leukemia (AML)...
  33. ncbi request reprint Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, The James Cancer Hospital and The Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 9:1248-52. 2003
  34. ncbi request reprint Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes
    Shih Jiuan Chiu
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    J Control Release 112:199-207. 2006
    ..8 microM to 0.18 microM. In conclusion, Tf-conjugated liposomes are effective delivery vehicles for G3139 antisense oligos in TfR positive K562 cells and warrant further investigation as an in vivo oligo delivery vehicle...
  35. pmc FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA
    Blood 111:275-84. 2008
    ..These results provide the first evidence for the potential use of FTY720 as a therapeutic agent in a variety of B-cell malignancies, including CLL...
  36. pmc Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia
    Michael A Caligiuri
    Integrated Biomeducal Graduate Program, Comprehensive Cancer Center, Ohio State University, Columbus, OH 23240, USA
    Blood 110:1022-4. 2007
    ..Short-interfering RNA knockdown of mutant c-CBL present in MOLM-13 cells was growth inhibitory. In summary, novel mutations in c-CBL and CBL-b have been identified in human AML and may represent potential targets for novel therapeutics...
  37. ncbi request reprint Altered mRNA translation: possible mechanism for CML disease progression
    Danilo Perrotti
    Division of Human Cancer Genetics, Ohio State University, 440 Tzagournis Medical Research Bldg, 420 W 12 Avenue, Columbus, OH 43210, USA
    Cell Cycle 2:177-80. 2003
  38. ncbi request reprint BCR/ABL activates mdm2 mRNA translation via the La antigen
    Rossana Trotta
    Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson Medical College, Philadelphia, PA 19107, USA
    Cancer Cell 3:145-60. 2003
    ..By contrast, La overexpression led to increased MDM2 levels and enhanced resistance to apoptosis. Thus, La-dependent activation of mdm2 translation might represent an important molecular mechanism involved in BCR/ABL leukemogenesis...
  39. ncbi request reprint BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2
    Danilo Perrotti
    Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Nat Genet 30:48-58. 2002
    ..Our results indicate that BCR-ABL regulates the expression of C/EBPalpha by inducing hnRNP E2-which inhibits the translation of CEBPA mRNA...
  40. ncbi request reprint Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins
    Danilo Perrotti
    Thomas Jefferson University, Department of Microbiology and Immunology, Kimmel Cancer Institute, Philadelphia, PA 19107, USA
    Oncogene 21:8577-83. 2002
    ..The identification of the mRNA subsets associated with RNA-binding proteins upregulated in BCR/ABL-expressing cells should functionally link the process of leukemogenesis with alteration of mRNA metabolism...
  41. ncbi request reprint Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox
    Danilo Perrotti
    J Clin Oncol 22:582-4. 2004
  42. ncbi request reprint CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia
    Bao Tran H Truong
    Comprehensive Cancer Center and Department of Laboratory Medicine, University of California, San Francisco 94143 0128, USA
    Blood 101:1141-8. 2003
    ..Our results support the hypothesis that induction of C/EBP activity is a critical effect of tRA in APL. Furthermore, our findings suggest that targeted modulation of C/EBP activities could provide a new approach to therapy of AML...
  43. ncbi request reprint The biology of CML blast crisis
    Bruno Calabretta
    Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson Medical College, Philadelphia, PA 19107, USA
    Blood 103:4010-22. 2004
    ....
  44. pmc NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma
    Annamaria Galietta
    Department of Clinical Medicine, University of Milano Bicocca, Monza, Italy
    Blood 110:2600-9. 2007
    ..These results identify PSF as a novel NPM/ALK-binding protein and substrate, and suggest that PSF function may be perturbed in NPM/ALK-transformed cells...
  45. pmc Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells
    Clara Guerzoni
    Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson Medical College, 233 South and 10th Street, Philadelphia, PA 19107, USA
    Blood 107:4080-9. 2006
    ....
  46. pmc CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activities
    Young Jin Lee
    Dept of Laboratory Medicine, Box 0134, 513 Parnassus Ave, San Francisco, CA 94143, USA
    Blood 108:2416-9. 2006
    ..We also show that forced expression of C/EBPalpha or C/EBPepsilon in combination with ATRA treatment has a synergistic effect on survival of leukemic mice compared with either therapy alone...
  47. ncbi request reprint Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease
    Emily K Thomas
    Division of Experimental Hematology, Cincinnati Children s Research Foundation, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Cancer Cell 12:467-78. 2007
    ..These data demonstrate that Rac is an additional therapeutic target in p210-BCR-ABL-mediated MPD...
  48. pmc CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha
    Steffen Koschmieder
    Department of Medicine, Hematology and Oncology, University of Munster, M√ľnster Germany
    Blood 110:3695-705. 2007
    ..Because AML is characterized by arrested differentiation, our data suggest the inclusion of CDDO in the therapy of AML characterized by dysfunctional CEBPA expression...
  49. pmc hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis
    Angela Iervolino
    Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Mol Cell Biol 22:2255-66. 2002
    ..Together, these results suggest that the shuttling activity of hnRNP A1 is important for the nucleocytoplasmic trafficking of mRNAs that encode proteins influencing the phenotype of normal and BCR/ABL-transformed myeloid progenitors...

Research Grants7

  1. Role of RNA-Binding Proteins in BCR/ABL Leukemogenesis
    Danilo Perrotti; Fiscal Year: 2006
    ..3) To determine the BCR/ABL-dependent mechanisms regulating the expression/function of hnRNP K and determine whether hnRNP K function(s) is(are) required for BCR/ABL-induced leukemogenesis. ..
  2. Role of RNA-Binding Proteins in BCR/ABL Leukemogenesis
    Danilo Perrotti; Fiscal Year: 2003
    ..3) To determine the BCR/ABL-dependent mechanisms regulating the expression/function of hnRNP K and determine whether hnRNP K function(s) is(are) required for BCR/ABL-induced leukemogenesis. ..
  3. Role of RNA-Binding Proteins in BCR/ABL Leukemogenesis
    Danilo Perrotti; Fiscal Year: 2004
    ..3) To determine the BCR/ABL-dependent mechanisms regulating the expression/function of hnRNP K and determine whether hnRNP K function(s) is(are) required for BCR/ABL-induced leukemogenesis. ..
  4. Role of RNA-Binding Proteins in BCR/ABL Leukemogenesis
    Danilo Perrotti; Fiscal Year: 2005
    ..3) To determine the BCR/ABL-dependent mechanisms regulating the expression/function of hnRNP K and determine whether hnRNP K function(s) is(are) required for BCR/ABL-induced leukemogenesis. ..
  5. Role of RNA Binding Proteins in BCR/ABL Leukemogenesis
    Danilo Perrotti; Fiscal Year: 2009
    ..Thus, it is clear that, if successful, the proposed research will have a strong impact on leukemia research and patient care. ..
  6. Role of RNA Binding Proteins in BCR/ABL Leukemogenesis
    Danilo Perrotti; Fiscal Year: 2010
    ..Thus, it is clear that, if successful, the proposed research will have a strong impact on leukemia research and patient care. ..